{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T20:29:23Z","timestamp":1780518563614,"version":"3.54.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T00:00:00Z","timestamp":1731715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T00:00:00Z","timestamp":1731715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007833","name":"Hamad Medical Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007833","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Psoriasis, an autoimmune inflammatory disease characterized by hyperproliferation of keratinocytes, affects 0.2\u20134.8% of the global population. The disease manifests primarily as plaque psoriasis, causing chronic physical and psychological burdens. Although numerous treatments exist, there is ongoing exploration for novel therapies due to concerns about the toxicity, efficacy, and costs of current options. An A3 adenosine receptor (A3AR) agonist called Piclidenoson has been shown to reduce inflammation and could be used to treat moderate to severe psoriasis. This meta-analysis evaluates the safety and efficacy of Piclidenoson in psoriasis treatment. This meta-analysis was conducted accordance with the PRISMA guidelines and has been registered on PROSPERO (CRD42024566459). A comprehensive search on Cochrane CENTRAL, PubMed\/MEDLINE, and Google Scholar was conducted up to July 2024. Included studies were randomized controlled trials (RCTs) involving Piclidenoson. Efficacy outcomes included PASI 75 and PGA 0 or 1, while safety outcomes included adverse events. Pooled outcomes were presented as odds ratio (OR) with 95% confidence intervals (CI). Statistical analysis employed the Mantel-Haenszel random-effects model, and heterogeneity was assessed using the I<jats:sup>2<\/jats:sup> and X<jats:sup>2<\/jats:sup>index. Three RCTs with 574 patients (313 Piclidenoson, 261 placebo) met the inclusion criteria. The pooled analysis showed no significant difference in achieving PASI 75 between Piclidenoson and placebo (OR: 1.62, 95% CI 0.70\u20133.75, <jats:italic>P<\/jats:italic>\u2009=\u20090.26, I<jats:sup>2<\/jats:sup>\u2009=\u200912%). However, Piclidenoson significantly improved PGA scores (OR: 2.74, 95% CI 1.22\u20136.16, <jats:italic>P<\/jats:italic>\u2009=\u20090.01, I\u00b2=0%). Safety assessment revealed no significant differences in adverse events, including nervous system, gastrointestinal, musculoskeletal, renal, and infections, compared to placebo. Piclidenoson demonstrates a significant improvement in PGA scores and a favorable safety profile, suggesting it could be a valuable addition to plaque-like psoriasis treatment. Further research with larger, longer-term RCTs is needed to confirm its efficacy and optimize clinical use.<\/jats:p>","DOI":"10.1007\/s00403-024-03506-y","type":"journal-article","created":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T08:30:27Z","timestamp":1731745827000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of Piclidenoson in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"317","author":[{"given":"Muhammad Zain","family":"Ul Haq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Shaukat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laveeza","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shahmeer Ullah","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ahsan","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Nabeel","family":"Saddique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gharira","family":"Batool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,16]]},"reference":[{"issue":"8","key":"3506_CR1","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1002\/ACR.23743","volume":"71","author":"L Eder","year":"2019","unstructured":"Eder L, Widdifield J, Rosen CF, Cook R, Lee KA, Alhusayen R, Paterson MJ, Cheng SY, Jabbari S, Campbell W, Bernatsky S, Gladman DD, Tu K (2019) Trends in the prevalence and incidence of Psoriasis and Psoriatic Arthritis in Ontario, Canada: a Population-based study. Arthritis Care Res 71(8):1084\u20131091. https:\/\/doi.org\/10.1002\/ACR.23743","journal-title":"Arthritis Care Res"},{"issue":"11","key":"3506_CR2","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1001\/JAMADERMATOL.2018.2972","volume":"154","author":"AC Gamret","year":"2018","unstructured":"Gamret AC, Price A, Fertig RM, Lev-Tov H, Nichols AJ (2018) Complementary and alternative Medicine therapies for Psoriasis: a systematic review. JAMA Dermatology 154(11):1330\u20131337. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2018.2972","journal-title":"JAMA Dermatology"},{"key":"3506_CR3","unstructured":"Nair PA, Badri T (2023) Psoriasis. StatPearls. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK448194\/"},{"issue":"14","key":"3506_CR4","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.2165\/11634980-000000000-00000","volume":"72","author":"PM Laws","year":"2012","unstructured":"Laws PM, Young HS (2012) Current and emerging systemic treatment strategies for psoriasis. Drugs 72(14):1867\u20131880. https:\/\/doi.org\/10.2165\/11634980-000000000-00000","journal-title":"Drugs"},{"key":"3506_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/PTT.S328575","volume":"12","author":"A Al-Janabi","year":"2022","unstructured":"Al-Janabi A, Yiu ZZN (2022) Biologics in Psoriasis: updated perspectives on Long-Term Safety and Risk Management. Psoriasis: Targets Therapy 12:1. https:\/\/doi.org\/10.2147\/PTT.S328575","journal-title":"Psoriasis: Targets Therapy"},{"issue":"4","key":"3506_CR6","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/J.BCP.2008.05.032","volume":"76","author":"A Ochaion","year":"2008","unstructured":"Ochaion A, Bar-Yehuda S, Cohen S, Amital H, Jacobson KA, Joshi BV, Gao ZG, Barer F, Patoka R, Del Valle L, Perez-Liz G, Fishman P (2008) The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB\/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats. Biochem Pharmacol 76(4):482\u2013494. https:\/\/doi.org\/10.1016\/J.BCP.2008.05.032","journal-title":"Biochem Pharmacol"},{"key":"3506_CR7","doi-asserted-by":"publisher","unstructured":"Stamp LK, Hazlett J, Roberts RL, Frampton C, Highton J, Hessian PA (2012) Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action. Arthritis Res Therapy 14(3). https:\/\/doi.org\/10.1186\/AR3871","DOI":"10.1186\/AR3871"},{"key":"3506_CR8","doi-asserted-by":"publisher","unstructured":"Cohen S, Barer F, Itzhak I, Silverman MH, Fishman P (2018) Inhibition of IL-17 and IL-23 in Human Keratinocytes by the A3 Adenosine Receptor Agonist Piclidenoson. Journal of Immunology Research, 2018. https:\/\/doi.org\/10.1155\/2018\/2310970","DOI":"10.1155\/2018\/2310970"},{"issue":"7\u20138","key":"3506_CR9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/J.DRUDIS.2011.10.007","volume":"17","author":"P Fishman","year":"2012","unstructured":"Fishman P, Bar-Yehuda S, Liang BT, Jacobson KA (2012) Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discovery Today 17(7\u20138):359\u2013366. https:\/\/doi.org\/10.1016\/J.DRUDIS.2011.10.007","journal-title":"Drug Discovery Today"},{"issue":"6","key":"3506_CR10","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/JDV.19811","volume":"38","author":"KA Papp","year":"2024","unstructured":"Papp KA, Beyska-Rizova S, Gantcheva ML, Slavcheva Simeonova E, Brezoev P, Celic M, Groppa L, Blicharski T, Selmanagic A, Kalicka-Dudzik M, Calin CA, Trailovic N, Ramon M, Bareket-Samish A, Harpaz Z, Farbstein M, Silverman MH, Fishman P (2024) Efficacy and safety of piclidenoson in plaque psoriasis: results from a randomized phase 3 clinical trial (COMFORT-1). J Eur Acad Dermatol Venereol 38(6):1112\u20131120. https:\/\/doi.org\/10.1111\/JDV.19811","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"3506_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/J.1468-3083.2011.04078.X","volume":"26","author":"M David","year":"2012","unstructured":"David M, Akerman L, Ziv M, Kadurina M, Gospodinov D, Pavlotsky F, Yankova R, Kouzeva V, Ramon M, Silverman MH, Fishman P (2012) Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. J Eur Acad Dermatology Venereology: JEADV 26(3):361\u2013367. https:\/\/doi.org\/10.1111\/J.1468-3083.2011.04078.X","journal-title":"J Eur Acad Dermatology Venereology: JEADV"},{"key":"3506_CR12","doi-asserted-by":"publisher","unstructured":"Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hr\u00f3bjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S.,\u2026 Moher, D. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 372. https:\/\/doi.org\/10.1136\/BMJ.N71","DOI":"10.1136\/BMJ.N71"},{"key":"3506_CR13","doi-asserted-by":"publisher","unstructured":"Sterne, J. A. C., Savovi\u0107, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H. Y., Corbett, M. S., Eldridge, S. M., Emberson, J. R., Hern\u00e1n, M. A., Hopewell, S., Hr\u00f3bjartsson, A., Junqueira, D. R., J\u00fcni, P., Kirkham, J. J., Lasserson, T., Li, T., Higgins, J. P. T. (2019). RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 366. https:\/\/doi.org\/10.1136\/BMJ.L4898","DOI":"10.1136\/BMJ.L4898"},{"issue":"3","key":"3506_CR14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/J.1468-3083.2011.04078.X","volume":"26","author":"M David","year":"2012","unstructured":"David M, Akerman L, Ziv M, Kadurina M, Gospodinov D, Pavlotsky F, Yankova R, Kouzeva V, Ramon M, Silverman MH, Fishman P (2012) Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. J Eur Acad Dermatol Venereol 26(3):361\u2013367. https:\/\/doi.org\/10.1111\/J.1468-3083.2011.04078.X","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3506_CR15","unstructured":"Treatment of Plaque-Type Psoriasis With Oral CF101: Data from a Phase II\/III Multicenter, Randomized, Controlled Trial - PubMed. (n.d.). Retrieved July 7 (2024) from https:\/\/pubmed.ncbi.nlm.nih.gov\/27537992\/"},{"issue":"3","key":"3506_CR16","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/J.JAAD.2011.01.022","volume":"66","author":"A Robinson","year":"2012","unstructured":"Robinson A, Kardos M, Kimball AB (2012) Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol 66(3):369\u2013375. https:\/\/doi.org\/10.1016\/J.JAAD.2011.01.022","journal-title":"J Am Acad Dermatol"},{"key":"3506_CR17","doi-asserted-by":"publisher","unstructured":"Aggarwal P, Fleischer AB (2024) IL-17 and IL-23 inhibitors have the fastest time to Meaningful Clinical response for Plaque Psoriasis: A Network Meta-Analysis. J Clin Med 13(17). https:\/\/doi.org\/10.3390\/JCM13175139","DOI":"10.3390\/JCM13175139"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03506-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03506-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03506-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T21:31:25Z","timestamp":1731792685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03506-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,16]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3506"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03506-y","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,16]]},"assertion":[{"value":"29 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication is not applicable as this study involves publicly available data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}